Sun Pharma, Dr Reddy’s, Aurobindo recall products in the U.S. market
- Post By :
- Source: PTI
- Date: 14 Mar,2021
Leading home grown drug makers Sun Pharma, Dr Reddy’s Laboratories, Aurobindo Pharma and Jubilant Pharma are remembering products in the U.S. market, the world’s largest market for pharmaceutical products, for various reasons.
As per the latest Enforcement Report from the U.S. Food and Drug Administration (USFDA), Sun Pharma is remembering Cequa ophthalmic solution, which is used to treat chronic dry eye.
The Princeton (NJ) based firm initiated the nationwide recall of the affected lot on February 22, this year, it added.
Similarly, Dr Reddy’s Laboratories is recalling 10,440 (90-count) and 2,24,710 (500 count) bottles of Atorvastatin Calcium tablets from the U.S. market.
The Hyderabad-based company is recalling the drug, which can be used to prevent cardiovascular disease, for”failed impurities/degradation specifications”, the USFDA stated.
The U.S.-based unit of this medication important initiated the nationwide recall on February 19, 2021, and the USFDA has categorised it as Class III remember that’s initiated at a”situation in which use of, or exposure to, a violative product is unlikely to cause adverse health consequences”.
The drug firm is also remembering 16,449 bottles of Progesterone Capsules (200 mg), used to induce menstrual periods in women who have not yet reached menopause, in the U.S. market for”unsuccessful dissolution specifications”.
“Famotidine 20mg and ibuprofen 400mg tablets were found in a great deal of famotidine 40mg,” the USFDA noted.
The company initiated the nationwide recall on January 20 and the USFDA has classified the action as Class II.
In any case, Salisbury-based Jubilant Cadista Pharmaceuticals is recalling 6,35,400 cartons of Methylprednisolone tablets, prescribed for its anti-inflammatory and immunosuppressive effects, in the American market due to”Illegible tag”.
“Customer complaint received of misalignment print of the printed dosing instructions on the blister card,” that the USFDA said.
The company initiated the nationwide recall on February 19 and the USFDA has classified the action as a Class III recall.